Bioventus (BVS) investor relations material

Executive summary

• Q2 2026 revenue reached $153.2 million, up 4% year-over-year, with double-digit growth in Pain Treatments, especially DUROLANE therapy.

• Net income for Q2 2026 was $36.2 million, a significant increase from $9.3 million in Q2 2025, benefiting from a $24.6 million deferred tax asset valuation allowance removal.

• Adjusted EBITDA for Q2 was $35.3 million, up 4.5% year-over-year, with a 23% margin.

• The Board initiated a review of strategic alternatives, including a potential sale, following unsolicited acquisition interest.

• Full-year guidance reaffirmed, reflecting confidence in long-term growth drivers such as PRP, PNS, Ultrasonics, and International.

Financial highlights

• Q2 2026 net sales were $153.2 million, up 4% year-over-year; gross profit was $105.7 million (69.0% margin).

• Adjusted EBITDA was $35.3 million, up from $33.8 million, with a 23% margin.

• Adjusted EPS was $0.22, up from $0.21 last year; GAAP EPS rose to $0.47 from $0.11.

• Cash from operations totaled $20 million for the quarter; cash and equivalents at quarter-end were $29.5 million.

• $24 million in debt repaid during the quarter; $46 million year-to-date; long-term debt at $229.7 million as of June 27, 2026.

Outlook and guidance

• Full-year 2026 guidance reaffirmed: net sales expected at $600–$610 million, adjusted EPS $0.75–$0.79, and cash from operations $84–$89 million.

• Revenue growth expected to accelerate in the second half, with cash from operations projected to double compared to the first half.

• Anticipates revenue increases in Surgical Solutions and acceleration in PNS and PRP segments.

• Sufficient liquidity expected for the next twelve months, supported by cash, revolver capacity, and operating cash flows.